Journals / Bursa Devlet Hastanesi Bülteni / 1998 / Cilt: 14 - Sayı: 1

Usage of granulocyte colony stimulating factor in addition to antimicrobial therapy in febrile neutropenia

Febril nötropenide ampirik antimikrobiyal tedaviye ek olarak granülosit koloni stimüle edici faktör kullanımı

Pages
61–63
Publication Date
2022-10-10
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

As a result it was concluded that a more detailed study should be performed to identify the patic.it group in whom G-CSF is being used rationally with this indication.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:60 febrile episodes were evaluated in this open randomized study to demonstrate the clinical effectiveness of usage of granulocyte colony stimulating factor (G-CSF) in addition to empiric antimicrobial treatment in febrile neutropenic patients with haematological malignant disease.
📊
Key Findings & Data:In 30 episodes G-CSF was used in a dose of 5 mcg/kg body weight as a mean of 10 days subcutaneously.
💡
Conclusion & Impact:As a result it was concluded that a more detailed study should be performed to identify the patic.it group in whom G-CSF is being used rationally with this indication.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

60 febrile episodes were evaluated in this open randomized study to demonstrate the clinical effectiveness of usage of granulocyte colony stimulating factor (G-CSF) in addition to empiric antimicrobial treatment in febrile neutropenic patients with haematological malignant disease. In 30 episodes G-CSF was used in a dose of 5 mcg/kg body weight as a mean of 10 days subcutaneously. No significant difference was demonstrated between two groups one having G-CSF in combination with empiric antibiotic treatment and the other with empiric antibiotic alone when compared according to the mortality rates due to infection and w rate of response to fever. As a result it was concluded that a more detailed study should be performed to identify the patic.it group in whom G-CSF is being used rationally with this indication.

Özet

Hematolojik malign hastalığı bulunan febril nötropenili olgularda ampirik antimikrobiyal tedaviye ek olarak granülosit koloni stimule edici faktör (G-CSF) kullanımının klinik yararını test etmek için yapılan bu açık, prospektif randomize çalışmada 60 febril epizod değerlendirildi. 30 epizodda 5 mcg/kg dozda median 10 gün subkutan G-CSF kullanılan ve kullanılmayan gruplar arasında ampirik antibiyotik tedavisi ile ateş .yanıtı ve wfïkstyono. bdğil mortalité açısından anlamlı f ark bulunmadı G-CSF "nin bu endikasyonla rasyonel kullanımı için, etkin olduğu hasta grubunu tanımlayan daha kapsamlı çalışmaların gerekli olduğu kanaatine varıldı.

🔖

Cite This Article

ÖZKALEMKAŞ, F., OĞUZHAN, B., ALİ, R., TUNALI, A., ÖZÇELİK, T., ÖZKOCAMAN, V. (2022). Usage of granulocyte colony stimulating factor in addition to antimicrobial therapy in febrile neutropenia. Bursa Devlet Hastanesi Bülteni, Cilt: 14 - Sayı: 1, 61–63. https://ajindex.com/articles/469478